Overall, since the attenuated effect of CCL20-NAb on EMs ectopic lesions was demonstrated in vivo, it can be expected that CCL20-NAb might be a candidate for clinical use in the therapy of EMs in future. This evidence concerns the gene CCL20 and eosinophilia-myalgia syndrome.